Tom Frohlich

Prior to Chinook, Tom was VP of business development at Arbutus Biopharma where he played a key role in multiple transactions including the merger of Tekmira/Oncore and the spin-out of Genevant. Previously, Tom worked internationally at J&J and Merck in various roles leading commercial strategy across all stages of product development including the global launches of telaprevir and Stelara. Tom has a B.Sc. in biochemistry from the University of Victoria and an MBA from the University of Oxford.